NRA-CANDESARTAN TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

CANDESARTAN CILEXETIL

Mevcut itibaren:

NORA PHARMA INC

ATC kodu:

C09CA06

INN (International Adı):

CANDESARTAN

Doz:

4MG

Farmasötik formu:

TABLET

Kompozisyon:

CANDESARTAN CILEXETIL 4MG

Uygulama yolu:

ORAL

Paketteki üniteler:

15G/50G

Reçete türü:

Prescription

Ürün özeti:

Active ingredient group (AIG) number: 0135220001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2022-05-03

Ürün özellikleri

______________________________________________________________________________
_NRA-Candesartan Product Monograph_
_ Page 1 of 39_
PRODUCT MONOGRAPH
PR
NRA-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Nora Pharma Inc.
1565 Lionel-Boulet Blvd.
Varennes, Quebec
J3X 1P7
Submission Control Numbers: 256986
DATE OF PREPARATION:
May 3, 2022
______________________________________________________________________________
_NRA-Candesartan Product Monograph_
_ Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................3
SUMMARY PRODUCT
INFORMATION...........................................................................3
INDICATIONS AND CLINICAL
USE.................................................................................3
CONTRAINDICATIONS......................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................5
ADVERSE
REACTIONS.......................................................................................................9
DRUG
INTERACTIONS.....................................................................................................15
DOSAGE AND ADMINISTRATION
................................................................................19
OVERDOSAGE...................................................................................................................22
ACTION AND CLINICAL
PHARMACOLOGY...............................................................22
STORAGE AND
STABILITY.............................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................25
PART II: SCIENTIFIC
INFORMATION.....................................................................................26
PHARMACEUTICAL
INFORMATION....................